🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tianjin
Clinical trial register · China

Clinical Trials in Tianjin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China203 Tianjin Medical University Cancer Institute and Hospital170 Tianjin Medical University Second Hospital25 Tianjin Medical University25 Tianjin Medical University General Hospital17
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Tianjin

940 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors
NCT07170293Solid Cancers
DrugTunlametinib
Tianjin Medical University Second Hospital
Phase 2
15
Tianjin
2027-08-31
Not yet open
A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH.
NCT07747090Paroxysmal Nocturnal Hemoglobinuria
DrugsFXS6837·Eculizumab
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3
90
Tianjin
2026-12-10
Not yet open
Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer
NCT07781150Obesity, Overweight, Atypical Endometrial Hyperplasia, Endometrial Carcinoma Stage I
DrugMazdutide
Tongji Hospital
Phase 2
128
Zhengzhou, Wuhan, Changchun, Hangzhou, Shanghai, Tianjin
2026-11-01
Not yet open
Study of SGB-9768 in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT07796256PNH - Paroxysmal Nocturnal Hemoglobinuria
DrugSGB-9768
Suzhou Sanegene Bio Inc.
Phase 2
24
Tianjin, Hangzhou
2026-10-31
Not yet open
CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
NCT07830485Multiple Myeloma
DrugsDaratumumab·Lenalidomide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
24
Tianjin
2026-10-15
Not yet open
Phase 1 Study of F182112 in Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT07816341Autoimmune Hemolytic Anemia
DrugF182112 single-agent
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
12
Tianjin
2026-10-10
Recruiting
Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors
NCT07726446Biliary Tract Cancer (BTC)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2026-10
Not yet open
A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia A
NCT07788469Hemophilia A With Inhibitors
DrugElranatamab
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
20
Tianjin
2026-10
Not yet open
Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer
NCT07828756Pancreatic Cancer
DrugsAlbumin-Bound Paclitaxel·Capecitabine·Gemcitabine·Cisplatin
Tianjin Medical University Cancer Institute and Hospital
Phase 2
147
Tianjin
2026-09-30
Not yet open
Phase II Study of Trastuzumab Rezetecan Combined With Retlirafusp Alfa With or Without CAPOX as Perioperative Therapy for Resectable Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
NCT07802288Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
DrugsRetlirafusp alfa·Capox·Trastuzumab Rezetecan
Tianjin Medical University Cancer Institute and Hospital
Phase 2
80
Tianjin
2026-09-30
Not yet open
META 10-19 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT07689604Autoimmune Hemolytic Anemia (AIHA)
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
18
Tianjin
2026-09-20
Not yet open
A Study on the Efficacy of Different Doses of Oryz-Aspergillus Enzyme And Pancreatin Tablet in Treating Pancreatic Exocrine Insufficiency After Gastrointestinal Surgery
NCT07751367Pancreatic Exocrine Insufficiency, Adul
Tianjin Medical University Cancer Institute and Hospital
Not applicable
150
Tianjin
2026-09-18
Not yet open
A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 in Advanced Solid Tumors
NCT07806175Advanced Malignant Solid Tumors
Rongchang Pharmaceuticals Co., Ltd.
Phase 1/2
486
Beijing, Hunan, Zhejiang, Shandong, Shanghai, Shanxi, Tianjin
2026-09-15
Recruiting
CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia
NCT07652905Plasma Cell Leukemia (PCL)
DrugsIsatuximab·Bortezomib·Lenalidomide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
24
Tianjin
2026-09-15
Recruiting
CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
NCT07585760Multiple Myeloma (MM), Multiple Myeloma Light Chain Induced Renal Insufficiency
DrugIsatuximab
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
26
Tianjin
2026-09-10
Recruiting
Efficacy and Safety of Stereotactic Body Radiation Therapy for Spinal Metastases With Bilsky Grade 1c-3
NCT07809672Stereotactic Body Radiation Therapy (SBRT), Spinal Metastases
Tianjin Medical University Cancer Institute and Hospital
Not applicable
50
Tianjin
2026-09-03
Recruiting
Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
NCT07620275Multiple Myeloma
DrugKsvcbd
Chinese PLA General Hospital
Phase 1
9
Beijing, Tianjin
2026-09-03
Not yet open
Sphere-9 PAF China Study
NCT07789925Paroxysmal Atrial Fibrillation (PAF)
Medtronic Cardiac Ablation Solutions
Not applicable
180
Beijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang, Tianjin
2026-09-02
Recruiting
Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC
NCT07801287HCC - Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
20
Tianjin
2026-09-01
Recruiting
HDR Endorectal Brachytherapy With 3D-Printed Guidance and Local Shielding for Rectal Cancer Organ Preservation
NCT07786493Rectal Cancer, Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital
Not applicable
50
Tianjin
2026-09-01
Recruiting
Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer
NCT07817082Advanced Breast Cancer With Ultra-Low HER2 Expression
DrugTrastuzumab Rezetecan
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2026-09-01
Not yet open
Acupuncture for Heel Pain Syndrome
NCT07607223Heel Pain Syndrome
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Not applicable
150
Tianjin
2026-09-01
Not yet open
Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma
NCT07758062Glioblastoma
DrugsLevetiracetam·Temozolomide
Tianjin Medical University General Hospital
Phase 2
140
Tianjin
2026-09-01
Not yet open
HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
NCT07811986Multiple Myeloma (MM)
DrugDexamethasone
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2026-09-01
Recruiting
Glycoprotein IIb/IIIa PET/CT in Various GPIIb/IIIa-Related Disease
NCT07813559Thrombi, Thrombus, Brain, Thrombus
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2026-09-01
Not yet open
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
DrugOrforglipron
Eli Lilly and Company
Phase 3
2,001
Chengdu, Hefei, Jinan, Luoyang Shi, Nanjing, Ningbo, Qinhuangdao Shi, Tianjin
2026-09
Not yet open
A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes
NCT07591168Myelodysplastic Syndromes
DrugBL-M11D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
92
Tianjin
2026-09
Not yet open
Thiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI.
NCT07778940Leptomeningeal Metastasis
DrugThiotepa
Tianjin Medical University Cancer Institute and Hospital
Phase 2
50
Tianjin
2026-09
Not yet open
SBRT Combined With Reduced-Dose Anthracycline Chemotherapy and Toripalimab as Neoadjuvant Therapy for Localized High-Risk Undifferentiated Pleomorphic Sarcoma
NCT07817095Undifferentiated Pleomorphic Sarcoma (UPS)
DrugsLiposomal doxorubicin·Tislelizumab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
39
Tianjin
2026-09
Not yet open
A Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics
NCT07830199Solid Tumor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
208
Shenyang, Tianjin
2026-09
Not yet open
Daridorexant for Sleep Disturbance in Adults With Liver Cirrhosis
NCT07830303Liver Cirrhosis, Sleep Disturbance, Hepatic Encephalopathy
DrugDaridorexant
Wang Fengmei
Phase 4
180
Tianjin
2026-09
Not yet open
Yiqi Fumai Lyophilized Injection for Chronic Heart Failure Caused by Coronary Heart Disease
NCT07803471Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Coronary Heart Disease (CHD)
China Academy of Chinese Medical Sciences
Not applicable
100
Guangzhou, Zhengzhou, Jinan, Tianjin
2026-09
Not yet open
Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma
NCT07769658Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Observational
500
Guangzhou, Zhengzhou, Shanghai, Chengdu, Tianjin, Kunming
2026-09
Recruiting
Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia
NCT07188740DNMT3A Gene Mutation
DrugMetformin
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
32
Tianjin
2026-08-30
Not yet open
Baduanjin for Quality of Life in Pancreatic Cancer Chemotherapy
NCT07791550Pancreatic Neoplasms, Pancreatic Cancer, Drug-Related Side Effects and Adverse Reactions (MeSH Term)
Tianjin Medical University Cancer Institute and Hospital
Not applicable
96
Tianjin
2026-08-28
Not yet open
Five-Element Music Therapy for Psychological Distress in Pancreatic Cancer Chemotherapy
NCT07796906Pancreatic Neoplasms, Pancreatic Cancer, Anxiety, Depression and/or Anxiety Symptoms
Tianjin Medical University Cancer Institute and Hospital
Not applicable
320
Tianjin
2026-08-28
Recruiting
Evaluation of Clinical Efficacy and Mechanism of Hand Jing-Well Acupoint Transcutaneous Electrical Stimulation in Improving Post-Stroke Cognitive Impairment
NCT07736885Post-Stroke Cognitive Impairment (PSCI), Ischemic Stroke, Cognitive Dysfunction, Cognitive Disorder, Hemorrhagic Strokes
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Not applicable
70
Tianjin
2026-08-15
Not yet open
The Effect of Intraoperative Infusion of Esketamine on Cholestatic Pruritus in Patients Undergoing Hepatobiliary Surgery
NCT07760740Cholestatic Pruritus
DrugEsketamine
Tianjin Medical University General Hospital
Not applicable
100
Tianjin
2026-08-15
By invitation
A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies
NCT07784309Acute T Cell Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory, Acute Myeloid Leukemia (AML), T Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
13
Tianjin
2026-08-15
Not yet open
Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC
NCT07749924Bladder Cancer, Non-Muscle-Invasive Bladder Cancer (NMIBC)
Tianjin Medical University Second Hospital
Not applicable
670
Daqing, Nanchang, Tianjin
2026-08-10
Recruiting
A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting
NCT07709897Prevention of Postoperative Nausea and Vomiting
DrugPalonosetron hydrochloride
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 2
260
Shanghai, Tianjin
2026-08-06
Not yet open
Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD
NCT07393685Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Influenza, Human, Virus Diseases
DrugBaloxavir Marboxil
Tianjin Medical University
Observational
300
Tianjin
2026-08-01
Not yet open
Autologous Hematopoietic Stem Cell Transplantation for Neurological Damage Associated With Hereditary Homocysteine Remethylation Disorders
NCT07757685Hereditary Homocysteine Remethylation Disorder
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
50
Tianjin
2026-08-01
Recruiting
Analysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Benefit Evaluation of Acupuncture Collaborative Management Regimen
NCT07763587Breast Neoplasms
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Not applicable
216
Tianjin
2026-08-01
Recruiting
Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive
NCT07712029Advanced Refractory Solid Tumors, EGFR Gene Overexpression
DrugsBecotatug Vedotin·Pucotenlimab
Tianjin Medical University Second Hospital
Phase 2
32
Tianjin
2026-08-01
Not yet open
EEG-Guided Cognitive Function Preservation in Patients With Brain Tumors
NCT07699172Glioma, Brain Neoplasm, Brain Tumor Adult
Bo Wang
Not applicable
10
Tianjin
2026-08-01
Not yet open
Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer
NCT07756008Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer, Bladder Cancer
DrugsDisitamab Vedotin·Tislelizumab
Tianjin Medical University Second Hospital
Phase 2/3
114
Tianjin
2026-08-01
Not yet open
Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
NCT07687004Multiple Myeloma (MM)
DrugSonrotoclax
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
50
Tianjin
2026-08-01
Not yet open
AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer
NCT07712094Neuroendocrine Cancer
DrugsIrinotecan·Cisplatin·Bevacizumab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
56
Baotou, Tongliao, Taiyuan, Tianjin
2026-08-01
Not yet open
Multi-Cohort Study of Zeprumetostat Combinations for Relapsed/Refractory PTCL
NCT07724782PTCL-NOS
DrugZeprumetostat
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2
33
Tianjin
2026-08-01
Not yet open
A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.
NCT07729033Advanced Biliary Tract Cancers
DrugsEnvafolimab·Sacituzumab tirumotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 2
28
Tianjin
2026-08
Not yet open
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300Depressive Disorder, Major
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,000
Beijing, Chaohu, Jinan, Linfen, Shanghai, Suzhou, Tianjin, Wenzhou
2026-08
Not yet open
Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects
NCT07697443Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
306
Guangzhou, Meizhou, Wuhan, Changsha, Chengdu, Tianjin
2026-08
Recruiting
NK Cells Plus ICI for SCLC Maintenance
NCT07759856Small Cell Lung Cancer
Tianjin First Central Hospital
Phase 2
42
Tianjin
2026-08
Not yet open
A Study of Bometase Alfa for Bleeding Control in Acquired Hemophilia A
NCT07789587Acquired Hemophilia A
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
20
Tianjin
2026-08
Not yet open
To Explore a Single-arm Phase II Study on Intestinal Microbiota Transplantation Combined With Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Rectal Cancer Under MSS/pMMR
NCT07738042Locally Advanced Rectal Cancer (LARC)
DrugsCapox·Sintilimab
Tianjin Medical University Cancer Institute and Hospital
Not applicable
46
Tianjin
2026-07-31
Recruiting
Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
NCT07733830Esophageal Cancer
DrugsAdebrelimab·Nab-paclitaxel·Carboplatin
Tianjin Medical University Cancer Institute and Hospital
Phase 2
120
Beijing, Zhengzhou, Shenyang, Taiyuan, Chengdu, Tianjin
2026-07-31
Recruiting
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
NCT07586202Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 2
68
Cheng Du Shi, Chengdu, Guangzhou, Jinan, Tianjin
2026-07-28
Recruiting
Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)
NCT07596784Generalized Myasthenia Gravis, gMG
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
20
Beijing, Changchun, Fuzhou, Jinan, Shanghai, Shijiazhuang, Taiyuan, Tianjin
2026-07-20
Not yet open
A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma
NCT07726160Relapse and/or Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
30
Tianjin
2026-07-20
Not yet open
BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)
NCT07751471AL Amyloidosis
DrugQLS4131
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2026-07-20
Recruiting
A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
NCT07518043Esophageal and/or Cardia Cancer, Melanoma, Urothelial Carcinoma (UC)
DrugOpdivo
Shanghai Henlius Biotech
Phase 1
174
Fuzhou, Hangzhou, Luoyang, Tianjin, Wenzhou, Wuhan, Xi'an
2026-07-15
Recruiting
Hypofractionated Radiotherapy After Complete Resection for Stage II/III Thymic Epithelial Tumors
NCT07691619Thymic Epithelial Tumor
Tianjin Medical University Cancer Institute and Hospital
Phase 2
49
Tianjin
2026-07-14
Not yet open
Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07721103Esophageal Squamous Cell Carcinoma (ESCC)
DrugPaclitaxel and Cisplatin
Tianjin Medical University Cancer Institute and Hospital
Phase 2
110
Tianjin
2026-07-14
Recruiting
A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasis
NCT07663331Adult Non-infectious Uveitis
DrugTyboWe Adalimumab
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4
30
Tianjin
2026-07-14
Recruiting
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
NCT07609862Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Waldenström Macroglobulinemia (WM)
DrugsLacutoclax·Rocbrutinib
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1/2
92
Tianjin
2026-07-14
Not yet open
Plasma ctDNA Monitoring in Pediatric Acute Leukemia
NCT07751588Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Observational
25
Tianjin
2026-07-11
Not yet open
Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP
NCT07687134Immune Thrombocytopenia
DrugEltrombopag
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
40
Tianjin
2026-07-10
Not yet open
A Randomized Controlled Trial of Prophylactic Rituximab to Reduce Clinically Significant EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
NCT07703657Allogeneic Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Reactivation, Clinically Significant EBV DNAemia
DrugRituximab
Yang Donglin
Not applicable
168
Tianjin
2026-07-09
Not yet open
Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients
NCT07703644Hematologic Neoplasms, Gram-Negative Bacterial Infections, Pseudomonas Aeruginosa Infection, Klebsiella Pneumoniae Infections
DrugCeftazidime-avibactam
Sizhou Feng
Observational
60
Tianjin
2026-07-09
Recruiting
MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
NCT07409454Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2026-07-07
Recruiting
HY001N for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.
NCT07748533Autoimmune Hemolytic Anemia (AIHA)
Juventas Cell Therapy Ltd.
Phase 1
9
Tianjin
2026-07-02
Not yet open
A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL)
NCT07676175Previously Untreated Peripheral T-Cell Lymphoma
DrugsVincristine Sulfate·Ifupinostat Hydrochloride·Doxorubicin Hydrochloride·Prednisone Acetate
BeBetter Med Inc
Phase 2
120
Guangzhou, Xi’an, Tianjin
2026-07-01
Not yet open
Phase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response
NCT07670715Locally Advanced Non-small Cell Lung Cancer (NSCLC), Thoracic Radiotherapy, Immune Checkpoint Inhibitors, Neoadjuvant Chemoimmunotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2026-07-01
Recruiting
Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
NCT07665190Hypopharyngeal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
52
Tianjin
2026-07-01
Recruiting
Temporal Interference Stimulation Treatment in Patients With Cognitive Impairment
NCT07643363Amnestic Mild Cognitive Impairment - aMCI, AD-MCI, AD - Alzheimer's Disease, FTD
Tianjin Huanhu Hospital
Not applicable
60
Tianjin
2026-07-01
Not yet open
A Single-arm, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Preventing Myelosuppression Caused by Topoisomerase I Inhibitor Type ADC Drugs
NCT07736001Tumor Patients
Tianjin Medical University Cancer Institute and Hospital
Not applicable
96
Tianjin
2026-07
Not yet open
Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney Disease
NCT07625774Chronic Kidney Disease
DrugHRS-7535
Shandong Suncadia Medicine Co., Ltd.
Phase 3
3,690
Tianjin, Hangzhou
2026-07
By invitation
Compassionate Administration of ZVS101e for Extended Treatment
NCT07307469Bietti Crystalline Corneoretinal Dystrophy
DrugZVS101e
Chigenovo Co., Ltd
Not applicable
32
Beijing, Guangzhou, Zhengzhou, Chengdu, Tianjin
2026-07
Not yet open
SYH2095 for Advanced Malignant Tumors: Phase I Study
NCT07692776Advanced Malignant Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Observational
140
Tianjin
2026-07
Not yet open
A Phase II Exploratory Study of SR604 Injection Evaluating the Safety and Efficacy in the Treatment of Congenital Coagulation Factor VII Deficiency
NCT07711158Factor VII Deficiency
Shanghai RAAS Blood Products Co., Ltd.
Phase 2
12
Tianjin
2026-07
Not yet open
Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer
NCT07358689NSCLC
DrugsDiphenhydramine·Tislelizumab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
120
Tianjin
2026-06-30
Active, closed
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
NCT07662122Obesity, Overweight
Boehringer Ingelheim
Phase 2
342
Huzhou, Jinan, Luoyang, Nanjing, Ningbo, Qinhuangdao, Tianjin, Yichang
2026-06-30
Recruiting
Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia
NCT07714512Aplastic Anemia
DrugIsatuximab
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
32
Tianjin
2026-06-30
Not yet open
Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal Cancer
NCT07691632Locally Advanced Colorectal Cancer, Colorectal Adenocarcinoma
DrugsDecitabine·Serplulimab·Capecitabine
Tianjin Medical University Cancer Institute and Hospital
Phase 2
35
Tianjin
2026-06-30
Recruiting
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
NCT07039422Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia
DrugIanalumab
Novartis Pharmaceuticals
Phase 2
60
Guangzhou, Dalian, Tianjin
2026-06-26
Recruiting
Monoamine Oxidase A PET/CT in Various MAO-A-Related Disease
NCT07685860Depression, Anxiety, Heart Injuries
Tianjin Medical University
Observational
200
Hefei, Qingdao, Tianjin
2026-06-25
Recruiting
Monoamine Oxidase B PET/CT in Various MAO-B-Related Disease
NCT07685873Parkinson Disease, Parkinson Disease Dementia, Parkinson's Disease and Parkinsonism
Tianjin Medical University
Observational
200
Hefei, Qingdao, Tianjin
2026-06-25
Recruiting
YH02 Injection for Intra-tumor Injection Therapy in Advanced Solid Tumors With Unresponsive or Failure-Treated Cases
NCT07697937Advanced Malignant Solid Tumor
Tianjin First Central Hospital
Phase 2
50
Tianjin
2026-06-23
Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies
NCT07619287Myeloid Malignancy
DrugBG-75202
BeOne Medicines
Phase 1
118
Lanzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Nanchang, Tianjin
2026-06-23
Recruiting
Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia
NCT07788456ITP - Immune Thrombocytopenia
DrugsEltrombopag·Daratumumab·Rituximab
Institute of Hematology & Blood Diseases Hospital, China
Phase 4
38
Tianjin
2026-06-22
Recruiting
Effect of Liposomal Bupivacaine TAPB Combined With Oxycodone PCIA on Postoperative Gastrointestinal Recovery in Patients Undergoing Major Abdominal Surgery
NCT07651722Postoperative Pain, Postoperative Ileus
DrugsOxycodone·Ropivacaine Hydrochloride·Sufentanil Citrate·Liposomal bupivacaine
Tianjin First Central Hospital
Not applicable
132
Tianjin
2026-06-16
Recruiting
Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Related CINV
NCT07726433Chemotherapy-Induced Nausea and Vomiting (CINV)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
56
Tianjin
2026-06-15
Not yet open
A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)
NCT07663838Randomized, Open-label, Safety, Tolerability
DrugGenSci142
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
30
Beijing, Nanjing, Nanchang, Changchun, Jinan, Taiyuan, Tianjin
2026-06-15
Recruiting
A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
NCT07606937Relapsed/Refractory Large B-cell Lymphoma
Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Phase EARLY_PHASE1
12
Beijing, Guangzhou, Suzhou, Shanghai, Chengdu, Tianjin
2026-06-12
Not yet open
Supraglottic Oxygenation Via Oral Transtracheal Catheter for Reducing the Incidence of Hypoxemia During ERCP Under Sedation
NCT07637721Choledocholithiasis With Cholecystitis With Obstruction, Obstructive Jaundice, Pancreatitis, Cholelithiasis
Zhejiang University
Not applicable
410
Tianjin, Hangzhou
2026-06-12
Active, closed
Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer
NCT07791602Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer, HNSCC
DrugCamrelizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
180
Beijing, Harbin, Shenyang, Taiyuan, Tianjin
2026-06-12
Active, closed
Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI
NCT07658105HCC - Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
60
Tianjin
2026-06-12
Active, closed
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
NCT07684898Severe Hemophilia A
DrugFRSW107
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3
60
Tianjin, Fuyang, Fuzhou, Guangzhou, Hefei, Jinan, Kunming, Nanning
2026-06-12
Not yet open
Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients
NCT07560475HER2positive, Advanced Breast Cancer, HER2 + Breast Cancer
DrugTrastuzumab Rezetecan
Tianjin Medical University Cancer Institute and Hospital
Phase 2
60
Tianjin
2026-06-10
Rows per page Showing 1–100 of 940
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/tianjin

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 940 of those studies with a site in Tianjin.

How many clinical trials are recruiting in Tianjin?

601 of the 940 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 153 have not yet opened recruitment, 162 are active but closed to new participants, and 24 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Tianjin), 940 studies
PhaseStudiesRecruitingShare
Phase 229819731.7%
Not applicable1428115.1%
Phase 31185412.6%
Phase 11168112.3%
Observational1148012.1%
Phase 1/21037411%
Phase EARLY_PHASE122172.3%
Phase 416111.7%
Phase 2/31161.2%

Most active sponsors

Lead sponsors with the most studies (Tianjin)
Lead sponsorStudiesRecruiting
Institute of Hematology & Blood Diseases Hospital, China203145
Tianjin Medical University Cancer Institute and Hospital170106
Tianjin Medical University2522
Tianjin Medical University Second Hospital2519
Tianjin Medical University General Hospital179
Hoffmann-La Roche133
Novartis Pharmaceuticals134
Tianjin Huanhu Hospital1210
Eli Lilly and Company117
Jiangsu HengRui Medicine Co., Ltd.118
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.